SLC7A2 (extracellular) Blocking Peptide (#BLP-NT103) is the original antigen used for immunization during Anti-SLC7A2 (extracellular) Antibody (#ANT-103) generation. The blocking peptide binds and ‘blocks’ Anti-SLC7A2 (extracellular) primary antibody, this makes it a good negative reagent control to help confirm antibody specificity in western blot and immunohistochemistry applications. This control is also often called a pre-adsorption control.
- Western blot analysis of Human THP-1 acute monocytic leukemia cells (lanes 1 and 6), mouse WEHI-231 B-cell lymphoma cells (lanes 2 and 7), rat RBL basophilic leukemia cells lysates (lanes 3 and 8), rat heart (lanes 4 and 9) and rat lung membranes (lanes 5 and 10):
- Expression of SLC7A2 (CAT-2) in mouse hippocampusImmunohistochemical staining of perfusion-fixed frozen mouse brain sections with Anti-SLC7A2 (extracellular) Antibody (#ANT-103), (1:300), followed by goat anti-rabbit-AlexaFluor-488. A. Staining in the hippocampal dentate gyrus region, showed SLC7A2 immunoreactivity (green) in neuronal profiles in the granule layer (G, vertical arrows) and in the hilus (H, horizontal arrows). B. Pre-incubation of the antibody with SLC7A2 (extracellular) Blocking Peptide (BLP-NT103), suppressed staining. Cell nuclei are stained with DAPI (blue).
- (C)KTYFKMNYTGLAE, corresponding to amino acid residues 151-163 of rat SLC7A2 (Accession B5D5N9).